ACRS

NASDAQ 已收盘

Aclaris Therapeutics

3.50 USD
0.000.00%
盘后 3.45 -1.43%
2026-11-19
市值
$545.63M
市盈率
—
EPS
-0.59
股息率
—
52 周区间
2.34 – 6.60
成交量
1.89M
Beta
0.94
目标价
9.82
52W 低 2.3452W 高 6.60
价格走势

公司简介

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational...